PARIS, May 3 (Reuters) – Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB will pay $2 billion in upfront payments and up to $200 million in potential future milestone payments for Candid Therapeutics, which is headquartered in California and is working on treatments for autoimmune diseases.
(Reporting by Sudip Kar-GuptaEditing by Tomasz Janowski)
